Sumesh Kachroo

1.8k total citations
91 papers, 1.4k citations indexed

About

Sumesh Kachroo is a scholar working on Epidemiology, Genetics and Rheumatology. According to data from OpenAlex, Sumesh Kachroo has authored 91 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Epidemiology, 28 papers in Genetics and 22 papers in Rheumatology. Recurrent topics in Sumesh Kachroo's work include Inflammatory Bowel Disease (28 papers), Microscopic Colitis (20 papers) and Rheumatoid Arthritis Research and Therapies (18 papers). Sumesh Kachroo is often cited by papers focused on Inflammatory Bowel Disease (28 papers), Microscopic Colitis (20 papers) and Rheumatoid Arthritis Research and Therapies (18 papers). Sumesh Kachroo collaborates with scholars based in United States, United Kingdom and Canada. Sumesh Kachroo's co-authors include Christopher M. Black, Jayanti Mukherjee, Axel Svedbom, Matthew W. Reynolds, John Waller, Hemant Phatak, James Piercy, Laurent Peyrin‐Biroulet, E Sullivan and Núria Lara and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Sumesh Kachroo

83 papers receiving 1.4k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Sumesh Kachroo 345 284 264 241 230 91 1.4k
W. Marieke Schoonen 276 0.8× 180 0.6× 120 0.5× 178 0.7× 321 1.4× 18 2.2k
Susana Plaza 248 0.7× 96 0.3× 177 0.7× 152 0.6× 243 1.1× 31 1.1k
L. Sailler 333 1.0× 414 1.5× 101 0.4× 111 0.5× 261 1.1× 135 2.0k
M Vilardell 273 0.8× 649 2.3× 95 0.4× 112 0.5× 171 0.7× 77 1.8k
Sean Robbins 428 1.2× 377 1.3× 68 0.3× 290 1.2× 197 0.9× 23 2.0k
Meng‐Jiun Chiou 215 0.6× 158 0.6× 58 0.2× 415 1.7× 86 0.4× 39 1.3k
Thomas Wilke 270 0.8× 57 0.2× 96 0.4× 681 2.8× 45 0.2× 166 1.8k
D.S. Keith 237 0.7× 63 0.2× 242 0.9× 444 1.8× 50 0.2× 37 2.5k
Jonas Lundkvist 80 0.2× 147 0.5× 104 0.4× 298 1.2× 45 0.2× 49 1.5k
Norio Hanafusa 228 0.7× 68 0.2× 85 0.3× 164 0.7× 139 0.6× 138 2.0k

Countries citing papers authored by Sumesh Kachroo

Since Specialization
Citations

This map shows the geographic impact of Sumesh Kachroo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumesh Kachroo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumesh Kachroo more than expected).

Fields of papers citing papers by Sumesh Kachroo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumesh Kachroo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumesh Kachroo. The network helps show where Sumesh Kachroo may publish in the future.

Co-authorship network of co-authors of Sumesh Kachroo

This figure shows the co-authorship network connecting the top 25 collaborators of Sumesh Kachroo. A scholar is included among the top collaborators of Sumesh Kachroo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumesh Kachroo. Sumesh Kachroo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhdanava, Maryia, Sumesh Kachroo, Aditi Shah, et al.. (2024). REAL-WORLD TREATMENT PERSISTENCE AMONG ADVANCED THERAPY-EXPERIENCED PATIENTS WITH ULCERATIVE COLITIS INITIATED ON USTEKINUMAB OR ADALIMUMAB. Inflammatory Bowel Diseases. 30(Supplement_1). S38–S38. 1 indexed citations
2.
Gagnon‐Sanschagrin, Patrick, M. Davidson, Cynthia Willey, et al.. (2024). The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study. Journal of Medical Economics. 27(1). 931–940. 1 indexed citations
3.
4.
Gagnon‐Sanschagrin, Patrick, M. Davidson, Cynthia Willey, et al.. (2023). Su1137 SUBOPTIMAL TREATMENT IN PATIENTS WITH CROHN'S DISEASE USING BIOLOGICS. Gastroenterology. 164(6). S–541. 1 indexed citations
5.
Zhdanava, Maryia, Sumesh Kachroo, Aditi Shah, et al.. (2023). S83 Real-World Treatment Persistence Among Advanced Therapy-Experienced Patients With Ulcerative Colitis Initiated on Ustekinumab or Adalimumab. The American Journal of Gastroenterology. 118(12S). S23–S23.
6.
Zhdanava, Maryia, Sumesh Kachroo, Aditi Shah, et al.. (2023). REAL-WORLD USTEKINUMAB PERSISTENCE IN PATIENTS WITH ULCERATIVE COLITIS ATTAINING THE MAINTENANCE PHASE. Gastroenterology. 164(4). S46–S47. 1 indexed citations
7.
Zhdanava, Maryia, Ruizhi Zhao, Ameur M. Manceur, et al.. (2023). Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab. Journal of Managed Care & Specialty Pharmacy. 29(8). 907–916. 3 indexed citations
8.
Sebastian, Shaji, Jenna Roberts, John Waller, et al.. (2018). PRO2 Based Remote Monitoring in Ulcerative Colitis: A Prospective Real World Study. Value in Health. 21. S258–S258. 1 indexed citations
9.
Sullivan, E, James Piercy, John Waller, Christopher M. Black, & Sumesh Kachroo. (2017). Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany. PLoS ONE. 12(4). e0175826–e0175826. 39 indexed citations
10.
Kachroo, Sumesh, Melissa Hamilton, Xianchen Liu, et al.. (2016). Oral anticoagulant discontinuation in patients with nonvalvular atrial fibrillation.. PubMed. 22(1). e1–8. 31 indexed citations
11.
Assche, Gert Van, Laurent Peyrin‐Biroulet, Andreas Sturm, et al.. (2016). Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months – Multicenter European cohort study. Digestive and Liver Disease. 48(6). 592–600. 41 indexed citations
12.
Peyrin‐Biroulet, Laurent, Gert Van Assche, Andreas Sturm, et al.. (2016). Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. Digestive and Liver Disease. 48(6). 601–607. 29 indexed citations
13.
Kachroo, Sumesh. (2015). Limnological Studies in Kashmir Lakes III Distribution of Phytoplankton in the Dal and Nagin. SHILAP Revista de lepidopterología.
14.
Holbrook, Tim, Robert Wood, Christopher M. Black, Xiaohan Hu, & Sumesh Kachroo. (2015). Avoidable Burden and Unmet Need Associated with Non-Radiographic Axial Spondyloarthritis Treatment: A Cross-Sectional European Study in the Real World Setting. Value in Health. 18(7). A653–A653.
15.
DeMuro, Carla, et al.. (2014). Literature Review Of Pro Measures Assessing Anticoagulant Therapy. Value in Health. 17(7). A495–A496. 1 indexed citations
16.
Kachroo, Sumesh, Hemant Phatak, Paul Dorian, et al.. (2014). Validation Of The Apixaban Cost-Effectiveness Model In Patients With Non-Valvular Atrial Fibrillation. Value in Health. 17(3). A113–A113. 1 indexed citations
17.
Biskupiak, Joseph, Sameer R. Ghate, Melissa Hamilton, et al.. (2014). ORAL ANTICOAGULANT (OAC) UTILIZATION IN ATRIAL FIBRILLATION AFTER THE INTRODUCTION OF NOVEL ORAL ANTICOAGULANTS. Journal of the American College of Cardiology. 63(12). A326–A326. 1 indexed citations
18.
Pan, Xianying, Sumesh Kachroo, Xianchen Liu, Hugh Kawabata, & Hemant Phatak. (2014). REAL WORLD DISCONTINUATION RATES WITH APIXABAN VERSUS WARFARIN, DABIGATRAN, OR RIVAROXABAN AMONG ATRIAL FIBRILLATION PATIENTS NEWLY INITIATED ON ANTICOAGULATION THERAPY: EARLY FINDINGS. Journal of the American College of Cardiology. 63(12). A415–A415. 10 indexed citations
19.
Spivey, Christina A., et al.. (2014). Discontinuation/Interruption of Warfarin Therapy in Patients with Non-Valvular Atrial Fibrillation. Value in Health. 17(7). A763–A763. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W. Marieke Schoonen Breakdown of academic impact, for papers by Susana Plaza Breakdown of academic impact, for papers by L. Sailler Breakdown of academic impact, for papers by M Vilardell Breakdown of academic impact, for papers by Sean Robbins Breakdown of academic impact, for papers by Meng‐Jiun Chiou Breakdown of academic impact, for papers by Thomas Wilke Breakdown of academic impact, for papers by D.S. Keith Breakdown of academic impact, for papers by Jonas Lundkvist Breakdown of academic impact, for papers by Norio Hanafusa
Rankless by CCL
2026